📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Novan

1.1 - Company Overview

Novan Logo

Novan

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of nitric oxide-based therapeutics, developing deliverable nitric oxide via its NITRICIL platform and offering ZELSUVMI, a topical gel (10.3% berdazimer) approved by the U.S. FDA for treating molluscum contagiosum.

Products and services

  • Deliverable Nitric Oxide Drug Development: Novan architects clinical-stage programs developing deliverable nitric oxide drugs, advancing candidates that leverage nitric oxide
  • NITRICIL: Novan’s proprietary nitric oxide-based technology platform engineers therapies for various medical needs by enabling development of deliverable nitric oxide drug candidates
  • ZELSUVMI: An FDA-approved topical gel with 10.3% berdazimer that treats molluscum contagiosum, formulated for topical application

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Novan

Evaxion Biotech Logo

Evaxion Biotech

HQ: Denmark Website
  • Description: Provider of AI-immunology™ platform-driven immunotherapies for cancer and infectious diseases, including EVX-01, a Phase 2 personalized cancer vaccine targeting patient-specific tumor antigens, and EVX-B1, a vaccine antigen against Staphylococcus Aureus, plus models PIONEER™, ObsERV™, and AI-DEEP™ for vaccine design and CPI response prediction.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Evaxion Biotech company profile →
Micreos Logo

Micreos

HQ: The Netherlands Website
  • Description: Provider of phage-based precision antimicrobials and engineered endolysins targeting pathogenic bacteria without harming the beneficial microbiome. Offerings include antimicrobial vectors; MEndoB for staphylococcal infections, including MRSA, for systemic/topical use; XZ.700 for S. aureus colonization in lesional skin (CTCL); and clinical/pre-clinical molecules for out-licensing, with focus areas including CTCL and AD.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Micreos company profile →
Vaxcyte Logo

Vaxcyte

HQ: United States Website
  • Description: Provider of vaccines and vaccine development technologies, including VAX-24, a 24-valent pneumococcal conjugate vaccine for preventing invasive pneumococcal disease in adults (FDA Breakthrough Therapy); VAX-31, a 31-valent pneumococcal conjugate candidate; the XpressCF cell-free platform for site-specific conjugation to enhance immunogenicity; and preclinical programs for Group A Strep, periodontitis, and Shigella.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Vaxcyte company profile →
Excelimmune Logo

Excelimmune

HQ: United States Website
  • Description: Provider of fully human recombinant polyclonal antibodies for therapeutics.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Excelimmune company profile →
Pattern Bioscience Logo

Pattern Bioscience

HQ: United States Website
  • Description: Provider of biotech diagnostic solutions to combat antibiotic resistance, including Digital Culture Technology, a single-cell analysis platform using digital cell reactors and machine learning to rapidly diagnose complex bacterial infections and determine antibiotic response without traditional culture, and the Pneumonia Action Panel for fast, comprehensive pathogen identification and susceptibility in hospitalized severe pneumonia.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Pattern Bioscience company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Novan

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Novan

2.2 - Growth funds investing in similar companies to Novan

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Novan

4.2 - Public trading comparable groups for Novan

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Novan

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Novan

What does Novan do?

Novan is a provider of nitric oxide-based therapeutics, developing deliverable nitric oxide via its NITRICIL platform and offering ZELSUVMI, a topical gel (10.3% berdazimer) approved by the U.S. FDA for treating molluscum contagiosum.

Who are Novan's competitors?

Novan's competitors and similar companies include Evaxion Biotech, Micreos, Vaxcyte, Excelimmune, and Pattern Bioscience.

Where is Novan headquartered?

Novan is headquartered in United States.

How many employees does Novan have?

Novan has 1,000 employees 🔒.

When was Novan founded?

Novan was founded in 2010 🔒.

What sector and industry vertical is Novan in?

Novan is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Novan

Who are the top strategic acquirers in Novan's sector and industry

Top strategic M&A buyers and acquirers in Novan's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Novan?

Top strategic M&A buyers groups and sectors for Novan include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Novan's sector and industry vertical

Which are the top PE firms investing in Novan's sector and industry vertical?

Top PE firms investing in Novan's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Novan's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Novan's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Novan's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Novan include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Novan's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Novan?

The key public trading comparables and valuation benchmarks for Novan include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Novan for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Novan with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Novan's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Novan with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Novan's' sector and industry vertical?

Access recent funding rounds and capital raises in Novan's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Novan